journal
https://read.qxmd.com/read/38634727/endotracheal-enucleation-and-para-toluenesulfonamide-injection-for-adenoid-cystic-carcinoma-in-the-upper-trachea-a-novel-therapeutic-approach
#1
Hsiao-Hung Lu, Shuenn-Wen Kuo
We present a case of an adenoid cystic carcinoma (ACC) located in the upper trachea, which resulted in significant airway blockage, that was unsuitable for surgical removal due to concerns about functional impairment. Instead, endotracheal enucleation via rigid bronchoscopy was performed initially, followed by the injection of a novel tumor ablation agent known as para-toluenesulfonamide (PTS). We detail the dosing regimen, effectiveness evaluation, and post-treatment follow-up. The study highlights the potential of PTS injection as a viable alternative treatment option for patients with ACC who cannot undergo surgical resection and feasibility of lipiodol to monitor treatment effect...
April 18, 2024: Thoracic Cancer
https://read.qxmd.com/read/38627917/circulating-smrp-and-ca-125-before-and-after-pleurectomy-decortication-for-pleural-mesothelioma
#2
JOURNAL ARTICLE
Juuso Paajanen, Ahmed Sadek, William G Richards, Yue Xie, Emanuele Mazzola, Kristina Sidopoulos, John Kuckelman, Ritu R Gill, Raphael Bueno
BACKGROUND: Tumor recurrence remains the main barrier to survival after surgery for pleural mesothelioma (PM). Soluble mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125) are established blood-based biomarkers for monitoring PM. We prospectively studied the utility of these biomarkers after pleurectomy decortication (PD). METHODS: Patients who underwent PD and achieved complete macroscopic resection with available preoperative SMRP levels were included...
April 16, 2024: Thoracic Cancer
https://read.qxmd.com/read/38623838/efficacy-and-safety-of-novel-immune-checkpoint-inhibitor-based-combinations-versus-chemotherapy-as-first-line-treatment-for-patients-with-extensive-stage-small-cell-lung-cancer-a-network-meta-analysis
#3
JOURNAL ARTICLE
Chuang Yang, Tiantian Xuan, Qing Gong, Xin Dai, Chengjun Wang, Rongyu Zhang, Wen Zhao, Jian Wang, Weiming Yue, Jisheng Li
BACKGROUND: Patients with extensive-stage small cell lung cancer (ES-SCLC) have an exceptionally poor prognosis and immune checkpoint inhibitors (ICIs) combined with etoposide-platinum is recommended as standard first-line therapy. However, which combination pattern is the best still remains unknown. This network meta-analysis was performed to compare the efficacy and safety of currently available patterns including an antiangiogenic agent containing regimen and probed into the most appropriate therapy for patients...
April 16, 2024: Thoracic Cancer
https://read.qxmd.com/read/38623823/investigating-the-predictive-factors-of-thoracic-aortic-invasion-and-surgical-outcomes-in-patients-with-primary-lung-cancer-a-retrospective-study
#4
JOURNAL ARTICLE
Hideomi Ichinokawa, Kazuya Takamochi, Mariko Fukui, Aritoshi Hattori, Takeshi Matsunaga, Kenji Suzuki
BACKGROUND: This study aimed to investigate predictors of thoracic aortic invasion in lung cancer patients using preoperative clinical and imaging characteristics and elucidate surgical outcomes in cases of aortic invasion. METHODS: Of the 4751 lung cancer patients who underwent surgery at our hospital, we included 126 (6.8%) who underwent left-sided surgery and in whom tumor appeared to be in contact with the thoracic aorta on preoperative imaging. The patients were divided into two groups: group A, 23 patients (18%) who underwent combined aortic resection (+); group B, 103 patients (82%) who did not undergo combined aortic resection (-)...
April 16, 2024: Thoracic Cancer
https://read.qxmd.com/read/38623812/continuous-immunotherapy-beyond-progression-in-clinical-practice-for-small-cell-lung-cancer
#5
JOURNAL ARTICLE
Ken Yamamoto, Taira Ninomaru, Hideaki Okada, Katsuya Hirano, Temiko Shimada, Akito Hata
In non-small-cell lung cancer, continuous immune-checkpoint inhibitors (ICIs) beyond progression are often used in clinical practice. On the other hand, there is almost no data on whether the concept of continuous ICIs beyond progression can be adopted in small-cell lung cancer (SCLC). We describe the effectiveness of continuous ICIs beyond progression in SCLC. Medical courses of SCLC patients treated with chemo-immunotherapy were retrospectively reviewed at our hospital. The study included 36 patients with a median age of 73 years (range 46-83 years) who introduced chemo-immunotherapy between September 2019 and December 2022...
April 16, 2024: Thoracic Cancer
https://read.qxmd.com/read/38622898/impact-of-concurrent-medications-on-the-outcome-of-immunotherapy-in-non-small-cell-lung-carcinoma
#6
JOURNAL ARTICLE
Jun Yamada, Takafumi Fukui, Atsuhiko Yatani, Chihiro Mimura, Kiyoko Fukuda, Daisuke Hazama, Naoko Katsurada, Tatsuya Nagano, Masatsugu Yamamoto, Motoko Tachihara
BACKGROUND: There have been reports on the impact of concurrent drugs on the outcome of immunotherapy for non-small cell lung carcinoma (NSCLC). However, the effect of some drugs, such as antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs), has not been clarified in patients with NSCLC. In the present study, we aimed to assess the association between concurrent drugs and the outcomes of immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy for patients with advanced NSCLC...
April 15, 2024: Thoracic Cancer
https://read.qxmd.com/read/38606839/surgical-outcomes-for-non-small-cell-lung-cancer-in-younger-adults-a-population-based-study
#7
JOURNAL ARTICLE
Zhirong Zhang, Huandong Huo, Feng Li, Jinbai Miao, Bin Hu, Shuo Chen
BACKGROUND: The surgical outcomes for younger patients with non-small cell lung cancer (NSCLC) remain uncertain. The aim of this study was to investigate the clinical features long-term survival outcomes in younger individuals with NSCLC following surgery. METHODS: We queried the Surveillance, Epidemiology, and End Results database from 2010 to 2017, selecting all pathologically confirmed NSCLC cases that underwent cancer-directed surgery. Younger patients were defined as those aged 18-50 years, while older patients were 51-80 years...
April 12, 2024: Thoracic Cancer
https://read.qxmd.com/read/38602166/real-world-evidence-of-efficacy-of-pembrolizumab-plus-chemotherapy-and-nivolumab-plus-ipilimumab-plus-chemotherapy-as-initial-treatment-for-advanced-non-small-cell-lung-cancer
#8
JOURNAL ARTICLE
Ayami Kaneko, Nobuaki Kobayashi, Kenji Miura, Hiromi Matsumoto, Kohei Somekawa, Tomofumi Hirose, Yukihito Kajita, Anna Tanaka, Shuhei Teranishi, Yu Sairenji, Hidetoshi Kawashima, Kentaro Yumoto, Toshinori Tsukahara, Nobuhiko Fukuda, Ryuichi Nishihira, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Makoto Kudo, Naoki Miyazawa, Takeshi Kaneko
BACKGROUND: For advanced non-small cell lung cancer (NSCLC), combination therapies including a PD-1 inhibitor plus chemotherapy or a PD-1 inhibitor, CTLA-4 inhibitor, and chemotherapy are standard first-line options. However, data directly comparing these regimens are lacking. This study compared the efficacy of pembrolizumab plus chemotherapy (CP) against nivolumab plus ipilimumab and chemotherapy (CNI) in a real-world setting. METHODS: In this multicenter retrospective study, we compared the efficacy and safety of CP and CNI as first-line therapies in 182 patients with stage IIIB-IV NSCLC...
April 11, 2024: Thoracic Cancer
https://read.qxmd.com/read/38597111/thoracic-skeletal-muscle-mass-predicts-mortality-in-patients-with-surgery-for-pleural-empyema-a-case-control-study
#9
JOURNAL ARTICLE
Christian Galata, Philipp Schiller, Lukas Müller, Ioannis Karampinis, Davor Stamenovic, Roland Buhl, Michael Kreuter, Eric Dominic Roessner
BACKGROUND: This study investigated the role of the thoracic skeletal muscle mass as a marker of sarcopenia on postoperative mortality in pleural empyema. METHODS: All consecutive patients (n = 103) undergoing surgery for pleural empyema in a single tertiary referral center between January 2020 and December 2022 were eligible for this study. Thoracic skeletal muscle mass index (TSMI) was determined from preoperative computed tomography scans. The impact of TSMI and other potential risk factors on postoperative in-hospital mortality was retrospectively analyzed...
April 10, 2024: Thoracic Cancer
https://read.qxmd.com/read/38587042/single-cell-rna-sequencing-reveals-aberrant-sphingolipid-metabolism-in-non-small-cell-lung-cancer-impacts-tumor-associated-macrophages-and-stimulates-angiogenesis-via-macrophage-inhibitory-factor-signaling
#10
JOURNAL ARTICLE
Luyan Shen, Jingtao Liu, Fengling Hu, Yifan Fang, Yaya Wu, Wei Zhao, Shaohua Ma
BACKGROUND: Sphingolipids not only serve as structural components for maintaining cell membrane fluidity but also function as bioactive molecules involved in cell signaling and the regulation of various biological processes. Their pivotal role in cancer cell development, encompassing cancer cell proliferation, migration, angiogenesis, and metastasis, has been a focal point for decades. However, the contribution of sphingolipids to the complexity of tumor microenvironment promoting cancer progression has been rarely investigated...
April 8, 2024: Thoracic Cancer
https://read.qxmd.com/read/38587029/immune-cell-related-prognostic-risk-model-and-tumor-immune-environment-modulation-in-esophageal-carcinoma-based-on-single-cell-and-bulk-rna-sequencing
#11
JOURNAL ARTICLE
Xiao Wen, Liu Pu, Zhang Wencheng, Ma Tengfei, Wang Guangshun
BACKGROUND: Immune cells play a pivotal role in the tumor microenvironment, exerting significant influence on tumor progression and patient outcomes, but the current biomarkers are insufficient to fully capture the complex and diverse tumor immune microenvironment and the impact of immunotherapy. METHODS: The advent of single-cell sequencing allows us to explore the tumor microenvironment at an unprecedented resolution, enabling the identification and characterization of distinct subsets of immune cells, thereby paving the way for the development of prognostic models using immune cells...
April 8, 2024: Thoracic Cancer
https://read.qxmd.com/read/38577812/correction-to-curcumin-induces-ferroptosis-in-non-small-cell-lung-cancer-via-activating-autophagy
#12
(no author information available yet)
No abstract text is available yet for this article.
April 5, 2024: Thoracic Cancer
https://read.qxmd.com/read/38576119/quantitative-evaluation-of-the-impact-of-relaxing-eligibility-criteria-on-the-risk-benefit-profile-of-drugs-for-lung-cancer-based-on-real-world-data
#13
JOURNAL ARTICLE
Huiyao Huang, Shuopeng Jia, Xin Wang, Huilei Miao, Hong Fang, Hanqing He, Dawei Wu, Yu Tang, Ning Li
INTRODUCTION: Restrictive eligibility criteria in cancer drug trials result in low enrollment rates and limited population diversity. Relaxed eligibility criteria (REC) based on solid evidence is becoming necessary for stakeholders worldwide. However, the absence of high-quality, favorable evidence remains a major challenge. This study presents a protocol to quantitatively evaluate the impact of relaxing eligibility criteria in common non-small cell lung cancer (NSCLC) protocols in China, on the risk-benefit profile...
April 4, 2024: Thoracic Cancer
https://read.qxmd.com/read/38572783/gut-microbiome-affects-the-response-to-immunotherapy-in-non-small-cell-lung-cancer
#14
JOURNAL ARTICLE
Shengnan Ren, Lingxin Feng, Haoran Liu, Yuke Mao, Zhuang Yu
BACKGROUND: Immunotherapy has revolutionized cancer treatment. Recent studies have suggested that the efficacy of immunotherapy can be further enhanced by the influence of gut microbiota. In this study, we aimed to investigate the impact of bacteria on the effectiveness of cancer immunotherapy by combining analysis of clinical samples with validation in animal models. METHODS: In order to characterize the diversity and composition of microbiota and its relationship with response to immune checkpoint inhibitors (ICIs), 16S ribosomal RNA (rRNA) and GC-MS sequencing was performed on 71 stool samples from patients with advanced non-small cell lung cancer (NSCLC) prior to treatment with immune checkpoint blockade (ICB)...
April 4, 2024: Thoracic Cancer
https://read.qxmd.com/read/38572774/surgery-challenges-and-postoperative-complications-of-lung-cancer-after-neoadjuvant-immunotherapy
#15
JOURNAL ARTICLE
Guangyu Bai, Xiaowei Chen, Yue Peng, Ying Ji, Fenglong Bie, Yang Liu, Zhenlin Yang, Shugeng Gao
BACKGROUND: In China, real-world data on surgical challenges and postoperative complications after neoadjuvant immunotherapy of lung cancer are limited. METHODS: Patients were retrospectively enrolled from January 2018 to January 2023, and their clinical and pathological characters were subsequently analyzed. Surgical difficulty was categorized into a binary classification according to surgical duration: challenging or routine. Postoperative complications were graded using Clavien-Dindo grades...
April 4, 2024: Thoracic Cancer
https://read.qxmd.com/read/38572623/considerations-for-multidisciplinary-management-of-synchronous-primary-breast-cancer-and-primary-lung-cancer-analysis-of-thirty-one-patients
#16
JOURNAL ARTICLE
Xue Chen, Yi-Fan Fang, Wan-Pu Yan
BACKGROUND: The simultaneous (synchronous) presence of primary breast cancer and primary lung cancer diagnosed in a single individual is not an uncommon phenomenon. However, reference data for treatment strategy is scarce and "chaotic". In the present study we discuss the management strategy for this group of patients. METHODS: We retrospectively reviewed patients in the primary breast cancer database of the Breast Center and the primary lung cancer database of the Thoracic Surgery Department I of Peking University Cancer Hospital...
April 4, 2024: Thoracic Cancer
https://read.qxmd.com/read/38567710/navigating-venous-thromboembolism-risks-in-lung-cancer-patients
#17
LETTER
Si-Wai Vivian Chiu, Chao-Ming Hung, Jiun-Rung Chen, Li-Ren Yeh, Chong-Chi Chiu
No abstract text is available yet for this article.
April 3, 2024: Thoracic Cancer
https://read.qxmd.com/read/38558529/identification-of-a-risk-score-model-based-on-tertiary-lymphoid-structure-related-genes-for-predicting-immunotherapy-efficacy-in-non-small-cell-lung-cancer
#18
JOURNAL ARTICLE
Shi-Qi Mei, Jia-Qi Liu, Zi-Jian Huang, Wei-Chi Luo, Ying-Long Peng, Zhi-Hong Chen, Yu Deng, Chong-Rui Xu, Qing Zhou
BACKGROUND: Tertiary lymphoid structures (TLSs) affect the prognosis and efficacy of immunotherapy in patients with non-small cell lung cancer (NSCLC), but the underlying mechanisms are not well understood. METHODS: TLSs were identified and categorized online from the Cancer Digital Slide Archive (CDSA). Overall survival (OS) and disease-free survival (DFS) were analyzed. GSE111414 and GSE136961 datasets were downloaded from the GEO database. GSVA, GO and KEGG were used to explore the signaling pathways...
April 1, 2024: Thoracic Cancer
https://read.qxmd.com/read/38558374/personalized-tumor-informed-circulating-tumor-dna-assay-for-detecting-minimal-residual-disease-in-non-small-cell-lung-cancer-patients-receiving-curative-treatments
#19
JOURNAL ARTICLE
Youjin Oh, Sung Mi Yoon, Jeeyeon Lee, Joo Hee Park, Soowon Lee, Timothy Hong, Liam Il-Young Chung, Sumedha Sudhaman, Timothy Riddell, Charuta C Palsuledesai, Michael Krainock, Minetta C Liu, Young Kwang Chae
BACKGROUND: Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for detection of minimal residual disease (MRD), monitoring treatment response, and early detection of recurrence in cancer patients. In this study, we explored the utility of ctDNA-based MRD detection to predict recurrence in a real-world cohort of primarily early-stage non-small cell lung cancer (NSCLC) patients treated with curative intent. METHODS: Longitudinal plasma samples were collected post curative-intent treatment from 36 patients with stage I-IV NSCLC...
April 1, 2024: Thoracic Cancer
https://read.qxmd.com/read/38553795/circ-postn-promotes-the-progression-and-reduces-radiosensitivity-in-esophageal-cancer-by-regulating-the-mir-876-5p-fyn-axis
#20
JOURNAL ARTICLE
Alan Chu, Chen Sun, Zongwen Liu, Shijia Liu, Mengxi Li, Rui Song, Lanlan Gan, Yongtai Wang, Ruitai Fan
BACKGROUND: Circular RNAs (circRNAs) play critical roles in the tumorigenesis and radiosensitivity of multiple cancers. Nevertheless, the biological functions of circRNA periostin (circ-POSTN) in esophageal cancer (EC) progression and radiosensitivity have not been well elucidated. METHODS: The expression of circ-POSTN, microRNA-876-5p (miR-876-5p), and proto-oncogene tyrosine-protein kinase (FYN) was analyzed by quantitative reverse transcription PCR (RT-qPCR)...
March 29, 2024: Thoracic Cancer
journal
journal
43030
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.